Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cloudbreak PharmaHKSE:02592 +1.64%11 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 704 Biotechnology companies, Cloudbreak Pharma ranks worse than 142045.31% on this metric.
The historical rank and industry rank for Cloudbreak Pharma's Days Payable or its related term are showing as below:
HKSE:02592's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.715 * Ranked among companies with meaningful Days Payable only.
Cloudbreak Pharma's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
The historical data trend for Cloudbreak Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02592 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Cloudbreak Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cloudbreak Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Cloudbreak Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cloudbreak Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cloudbreak Pharma (HKSE:02592) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #999999 out of 704 companies in the Biotechnology industry.
Is Cloudbreak Pharma's Days Payable too high?
Cloudbreak Pharma's current Days Payable is 0.00. Based on the distribution chart, Cloudbreak Pharma ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #999999 out of 704 companies for Days Payable. This places Cloudbreak Pharma in the lower half of its industry. The industry median Days Payable is 112.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cloudbreak Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cloudbreak Pharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Days Payable of 0.00. The current Days Payable is 0.00. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score
Get the complete analysis for HKSE:02592
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02592 has been successfully added to your 
